1月9日，生物股份涨5.06%，截至发稿，报17.45元/股，成交9.18亿元，换手率4.80%，总市值194.00亿 元。生物股份股价已经连续5天上涨，区间累计涨幅10.73%。 资料显示，金宇生物技术股份有限公司位于内蒙古自治区呼和浩特市经济技术开发区沙尔沁工业园区金 宇大街1号，成立日期1993年3月13日，上市日期1999年1月15日，公司主营业务涉及主要从事兽用生物 制品的研发、生产与销售。主营业务收入构成为：生物制药94.42%，其他收入3.18%，其他(补 充)2.40%。 截至发稿，聂启文累计任职时间59天，现任基金资产总规模9.27亿元，任职期间最佳基金回报4.27%， 任职期间最差基金回报-2.41%。 从基金十大重仓股角度 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 数据显示，易方达基金旗下1只基金重仓生物股份。易方达中证现代农业主题ETF（562900）三季度增 持1.96万股，持有股数23.91万股，占基金净值比例为2.79%，位居第八大重仓 ...

12月31日，生物股份涨1%，截至发稿，报15.15元/股，成交2.23亿元，换手率1.34%，总市值168.43亿 元。 资料显示，金宇生物技术股份有限公司位于内蒙古自治区呼和浩特市经济技术开发区沙尔沁工业园区金 宇大街1号，成立日期1993年3月13日，上市日期1999年1月15日，公司主营业务涉及主要从事兽用生物 制品的研发、生产与销售。主营业务收入构成为：生物制药94.42%，其他收入3.18%，其他(补 充)2.40%。 截至发稿，刘重杰累计任职时间7年243天，现任基金资产总规模328.73亿元，任职期间最佳基金回报 102.09%， 任职期间最差基金回报-36.57%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 责任编辑：小浪快报 从基金十大重仓股角度 数据显示，招商基金旗下1只基金重仓生物股份。招商中证畜牧养殖ETF（516670）三季度增持83.4万 股，持有股数360.29万股，占基金净值比例为3.95%，位居第八大重仓股。根据测算，今日浮盈赚取 ...

12月30日，生物股份跌1.3%，截至发稿，报15.19元/股，成交965.24万元，换手率0.06%，总市值168.87 亿元。 招商中证畜牧养殖ETF（516670）基金经理为刘重杰。 截至发稿，刘重杰累计任职时间7年242天，现任基金资产总规模328.73亿元，任职期间最佳基金回报 102.53%， 任职期间最差基金回报-35.89%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 责任编辑：小浪快报 资料显示，金宇生物技术股份有限公司位于内蒙古自治区呼和浩特市经济技术开发区沙尔沁工业园区金 宇大街1号，成立日期1993年3月13日，上市日期1999年1月15日，公司主营业务涉及主要从事兽用生物 制品的研发、生产与销售。主营业务收入构成为：生物制药94.42%，其他收入3.18%，其他(补 充)2.40%。 从基金十大重仓股角度 数据显示，招商基金旗下1只基金重仓生物股份。招商中证畜牧养殖ETF（516670）三季度增持83.4万 股，持有股数360.29万股，占 ...

12月24日，生物股份跌6.39%，截至发稿，报15.82元/股，成交2.10亿元，换手率1.15%，总市值175.88 亿元。 资料显示，金宇生物技术股份有限公司位于内蒙古自治区呼和浩特市经济技术开发区沙尔沁工业园区金 宇大街1号，成立日期1993年3月13日，上市日期1999年1月15日，公司主营业务涉及主要从事兽用生物 制品的研发、生产与销售。主营业务收入构成为：生物制药94.42%，其他收入3.18%，其他(补 充)2.40%。 从基金十大重仓股角度 数据显示，易方达基金旗下1只基金重仓生物股份。易方达中证现代农业主题ETF（562900）三季度增 持1.96万股，持有股数23.91万股，占基金净值比例为2.79%，位居第八大重仓股。根据测算，今日浮亏 损失约25.82万元。 易方达中证现代农业主题ETF（562900）成立日期2021年12月2日，最新规模8262.09万。今年以来收益 11.18%，同类排名3366/4197；近一年收益10.72%，同类排名3368/4157；成立以来亏损19.95%。 易方达中证现代农业主题ETF（562900）基金经理为宋钊贤、聂启文。 截至发稿，宋钊贤累计任 ...

易方达中证现代农业主题ETF（562900）基金经理为宋钊贤、聂启文。 截至发稿，宋钊贤累计任职时间5年110天，现任基金资产总规模583.14亿元，任职期间最佳基金回报 68.59%， 任职期间最差基金回报-28.55%。 12月22日，生物股份涨5.01%，截至发稿，报15.72元/股，成交7.79亿元，换手率4.53%，总市值174.77 亿元。 资料显示，金宇生物技术股份有限公司位于内蒙古自治区呼和浩特市经济技术开发区沙尔沁工业园区金 宇大街1号，成立日期1993年3月13日，上市日期1999年1月15日，公司主营业务涉及主要从事兽用生物 制品的研发、生产与销售。主营业务收入构成为：生物制药94.42%，其他收入3.18%，其他(补 充)2.40%。 从基金十大重仓股角度 数据显示，易方达基金旗下1只基金重仓生物股份。易方达中证现代农业主题ETF（562900）三季度增 持1.96万股，持有股数23.91万股，占基金净值比例为2.79%，位居第八大重仓股。根据测算，今日浮盈 赚取约17.93万元。 易方达中证现代农业主题ETF（562900）成立日期2021年12月2日，最新规模8262.09万。今年 ...

Group 1 - The core point of the article is that Haili Biological announced a board meeting to discuss the acquisition of minority shareholder rights in its subsidiary [1] - For the year 2024, Haili Biological's revenue composition is as follows: 57.81% from medical devices, 42.19% from veterinary biological products, and 0.01% from other businesses [1] - As of the report date, Haili Biological has a market capitalization of 4.5 billion yuan [1] Group 2 - The article highlights significant developments in the global chip industry, particularly the emergence of Google's TPU chip and its collaboration with Meta [1] - It mentions that Nvidia has experienced a market value loss of 4 trillion yuan, indicating a potential breach of its competitive advantage [1] - The CEO of Nvidia, Jensen Huang, is reportedly concerned about these developments [1]

Core Insights - The event themed "Creating a New Engine for the Development of the Biological Economy in Heilongjiang" highlighted the achievements of Harbin Pharmaceutical Group Biological Vaccine Co., Ltd. (referred to as "Harbin Vaccine") as a leading enterprise in veterinary biological products in Heilongjiang for 63 years, showcasing the synergy of resource endowment, technological reserves, and policy support in the region's biological economy [2] Group 1 - Harbin Vaccine has established a solid innovation foundation through its SPF experimental animal production base and deep collaborations with various research institutions, leading to significant growth in recent years [2] - The company has received 10 new veterinary drug certificates and generated nearly 10 million yuan in technology transfer income, with new product sales exceeding 20 million yuan, covering over 80% of the national market [2] Group 2 - Three key recommendations were proposed to address industry pain points: forming a provincial innovation consortium for veterinary biological products to integrate resources from universities, research institutions, and leading enterprises; establishing a risk warning mechanism for the supply chain; and creating a local supply-demand matching platform to promote the application of local vaccine products in large-scale breeding enterprises [3]

Group 1 - The core viewpoint of the news is that Jin Yu Biological Technology Co., Ltd. has seen a stock price increase of 5.02%, reaching 12.13 CNY per share, with a total market capitalization of 13.486 billion CNY [1] - The company, established on March 13, 1993, and listed on January 15, 1999, primarily engages in the research, production, and sales of veterinary biological products, with 94.42% of its revenue coming from biopharmaceuticals [1] - The trading volume for the stock was 340 million CNY, with a turnover rate of 2.56% [1] Group 2 - Among the top ten circulating shareholders of Jin Yu Biological, a fund under Southern Fund holds a significant position, having reduced its holdings by 93,300 shares in the third quarter, now owning 10.2491 million shares, which is 0.92% of the circulating shares [2] - The Southern CSI 1000 ETF (512100) has a total scale of 76.63 billion CNY and has achieved a year-to-date return of 21.59%, ranking 1964 out of 4206 in its category [2] - The fund manager, Cui Lei, has been in charge for 7 years and 20 days, with the fund's total asset size at 122.76 billion CNY, achieving a best return of 161.89% during the tenure [3]

Core Viewpoint - TianKang Pharmaceutical Co., Ltd. continues to face declining performance in the first three quarters of the year, with high accounts receivable and low capacity utilization, raising concerns from regulatory authorities regarding its expansion plans [1] Financial Performance - Revenue and net profit have declined for two consecutive years, with revenues of 1 billion yuan, 1.055 billion yuan, and 1.052 billion yuan from 2022 to 2024, and net profits of 204 million yuan, 165 million yuan, and 153 million yuan during the same period, reflecting year-on-year declines of 18.36% and 11.20% respectively [3] - For the first nine months of 2025, the company reported a year-on-year revenue decline of 20.49% and a net profit decline of 42.44%, while comparable companies in the industry saw average revenue growth of 1.60% and net profit growth of 49.06% [4] Accounts Receivable - The company's accounts receivable at the end of the reporting periods were 338 million yuan, 377 million yuan, and 364 million yuan, accounting for 10.40%, 10.70%, and 10.95% of total assets respectively [7] - As of June 2025, accounts receivable stood at 482 million yuan, with 72.32% from government procurement clients, and overdue amounts from direct sales and distribution clients totaling 42.81 million yuan [7] Capacity Utilization and Expansion Plans - The company plans to raise 527 million yuan for various projects, including 128 million yuan for the expansion of veterinary vaccine production and 105 million yuan for the renovation of brucellosis vaccine production [9] - The current production capacity for brucellosis vaccine is 150 million doses, with capacity utilization rates of 36.02%, 43.72%, 44.44%, and 34.61% over the reporting period [11] - Regulatory authorities have questioned the necessity and rationale for expanding production given the low overall capacity utilization and have requested further analysis of market demand for the new capacity [11][12]

Core Viewpoint - Yongshun Biological has demonstrated strong operational resilience with a slight increase in net profit despite a decrease in revenue, indicating effective cost control and product optimization strategies [1][2]. Financial Performance - In the first three quarters of 2025, Yongshun Biological achieved operating revenue of 180 million yuan, with a net profit attributable to shareholders of 30.28 million yuan, reflecting a year-on-year growth of 4.56% [1]. - The company's operating income decreased by 10.18% year-on-year, attributed to the cyclical fluctuations in the pig farming industry [2]. - The net cash flow from operating activities reached 74.66 million yuan, a significant increase of 34.97% year-on-year, indicating strong cash flow management [2]. - Asset impairment losses were reduced by 75.49% year-on-year, primarily due to improved inventory turnover and efficiency [2]. Product Development and Innovation - Yongshun Biological has focused on innovation, investing 15.31 million yuan in R&D, which is approximately 8.50% of its operating revenue [3]. - The company has recently obtained production licenses for two significant products: a quadrivalent inactivated vaccine for avian influenza and a bivalent inactivated vaccine for H5 subtype avian influenza, enhancing its market position in poultry vaccines [3]. - Additional product approvals include a new vaccine for pigeon newcastle disease and several other vaccines for swine diseases, indicating a robust pipeline for future growth [3]. Industry Outlook - The pig farming industry is expected to rebound in the fourth quarter, supported by policy adjustments and market corrections, positioning Yongshun Biological favorably for sustained growth in the upcoming industry cycle [4].